Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2014 (2014), Article ID 146530, 10 pages
http://dx.doi.org/10.1155/2014/146530
Review Article

Effectiveness and Safety of S-1-Based Therapy Compared with 5-Fluorouracil-Based Therapy for Advanced Colorectal Cancer: A Meta-Analysis

Department of Medical Oncology, The Cancer Institute, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China

Received 8 April 2014; Accepted 4 November 2014; Published 30 November 2014

Academic Editor: Daiming Fan

Copyright © 2014 Jiaxiang Ye et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Meyerhardt and R. J. Mayer, “Systemic therapy for colorectal cancer,” The New England Journal of Medicine, vol. 352, no. 5, pp. 476–487, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. B. H. O'Neil and R. M. Goldberg, “Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials,” The Oncologist, vol. 13, no. 10, pp. 1074–1083, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Shirasaka, Y. Shimamato, H. Ohshimo et al., “Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators,” Anti-Cancer Drugs, vol. 7, no. 5, pp. 548–557, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Huang, Y. Cao, L. Wu, C. Liao, Y. He, and F. Gao, “S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis,” Medical Oncology, vol. 28, no. 4, pp. 1004–1011, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. C. J. Bian, J. Zhu, and Q. Sun, “Clinical study of oxaliplatin plus S-1 in the treatment of advanced colorectal cancer,” Chinese Journal of Primary Medicine and Pharmacy, vol. 20, no. 20, pp. 3133–3134, 2013. View at Google Scholar
  7. Y. L. Gao, Y. M. Han, and J. F. Hou, “Clinical effect observation of S-1 combined with irinotecan for patients with advanced colorectal carcinoma,” Medical Innovation of China, vol. 10, no. 16, pp. 17–19, 2013. View at Google Scholar
  8. S. Kato, H. Andoh, M. Gamoh et al., “A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 (IRIS) plus bevacizumab (BV) and modified (m) FOLFIRI plus BV in patients (pts) with metastatic colorectal cancer (mCRC): first report of T-CORE0702,” Journal of Clinical Oncology, vol. 29, no. 4, p. 496, 2011. View at Google Scholar
  9. K. Muro, N. Boku, Y. Shimada et al., “Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study),” The Lancet Oncology, vol. 11, no. 9, pp. 853–860, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Ojima, K. Yamazaki, H. Kuwano et al., “Randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastatic colorectal cancer (mCRC),” European Journal of Cancer, vol. 47, supplement 1, pp. S427–S428, 2011. View at Google Scholar
  11. S. M. Tian, “S-1 plus irinotecan for second-line treatment of patients with metastatic colorectal cancer,” Journal of Qiqihar Medical College, vol. 32, no. 16, pp. 2580–2582, 2011. View at Google Scholar
  12. X. L. Wang, J. R. Peng, and X. H. Wang, “Clinical study of S-1 capsule combined with oxaliplatin in the treatment of patients with advanced colorectal carcinoma,” Journal of Modern Oncology, vol. 20, no. 10, pp. 2104–2106, 2012. View at Google Scholar
  13. Y. Wang, Y. S. Zhang, and J. Wang, “Clinical study of S-1 capsule plus oxaliplatin compared with FOLFOX6 in the treatment of patients with advanced colorectal carcinoma,” Anhui Medical Journal, vol. 34, no. 9, pp. 1309–1311, 2013. View at Google Scholar
  14. M. Xie, F. Ma, and H. Y. Li, “Clinical study of S-1 combined with oxaliplatin in the treatment of patients with advanced colorectal carcinoma,” Chinese Journal of Oncology Prevention and Treatment, vol. 5, no. 2, pp. 159–161, 2013. View at Google Scholar
  15. R. H. Xiong, Q. Ren, and X. R. Tian, “Clinical research of advanced colon carcinoma patients treated with S-1 combined with oxaliplatin,” Chinese Journal of Medicinal Guide, vol. 14, no. 7, pp. 1208–1210, 2012. View at Google Scholar
  16. Y. Yamada, D. Takahari, H. Matsumoto et al., “Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial,” The Lancet Oncology, vol. 14, no. 13, pp. 1278–1286, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Yang and X. F. Li, “Clinical study of irinotecan combined with tegafur compared with irinotecan combined with 5-fluorouracil in treatment of advanced rectal cancer,” Chinese Journal of Medicinal Guide, vol. 15, no. 7, pp. 1278–1279, 2013. View at Google Scholar
  18. H. Baba, K. Muro, H. Yasui et al., “Updated results of the FIRIS study: a phase II/III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC),” Journal of Clinical Oncology, vol. 29, no. 15, p. 3562, 2011. View at Google Scholar
  19. T. Otsuji, K. Yamazaki, H. Ojima et al., “Updated survival results of the randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastatic colorectal cancer (mCRC),” Journal of Clinical Oncology, vol. 30, no. 4, p. 586, 2012. View at Google Scholar
  20. J. P. T. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, The Cochrane Collaboration, 2011, http://handbook.cochrane.org/.
  21. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. D. A. Bennett, N. K. Latham, C. Stretton, and C. S. Anderson, “Capture-recapture is a potentially useful method for assessing publication bias,” Journal of Clinical Epidemiology, vol. 57, no. 4, pp. 349–357, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Komatsu, S. Yuki, and S. Sogabe, “Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab in patients with metastatic colorectal cancer,” Annals of Oncology, vol. 21, supplement 8, p. viii197, 2010. View at Google Scholar
  26. Y. Choi, T. Kim, S. Lee et al., “A phase I/II study of combination therapy of S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 15, Article ID e15023, 2009. View at Google Scholar
  27. A. Goto, Y. Yamada, S. Iwasa et al., “S-1 and irinotecan versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of 4 phase II studies,” European Journal of Cancer, vol. 49, supplement 2, pp. S551–S597, 2013. View at Google Scholar
  28. Y. S. Hong, Y. S. Park, H. Y. Lim et al., “S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial,” The Lancet Oncology, vol. 13, no. 11, pp. 1125–1132, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Y. Zang, I. J. Chung, H. S. Oh, K. U. Park, K. H. Lee, and B. Han, “Randomized phase II study of oxaliplatin and S-1 (OS) versus oxaliplatin and capecitabine (XELOX) in patients with advanced or recurrent colorectal cancer,” Journal of Clinical Oncology, vol. 30, no. 4, p. 595, 2012. View at Google Scholar
  30. M. Miwa, M. Ura, M. Nishida et al., “Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5 fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue,” European Journal of Cancer, vol. 34, no. 8, pp. 1274–1281, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. W. Ling, J. Fan, Y. Ma, and H. Wang, “Capecitabine-based chemotherapy for metastatic colorectal cancer,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 6, pp. 927–938, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. L. B. Saltz, S. Clarke, E. Díaz-Rubio et al., “Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 2013–2019, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. J. A. Ajani, J. Faust, K. Ikeda et al., “Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 6957–6965, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Chuah, B.-C. Goh, S.-C. Lee et al., “Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients,” Cancer Science, vol. 102, no. 2, pp. 478–483, 2011. View at Publisher · View at Google Scholar · View at Scopus